A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Mirador Therapeutics, Inc. · NCT07113522
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–80 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 140
- US sites recruiting
- 46
- Study start
- June 26, 2025
- Record last updated
- March 12, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
Being studied: MT-501; MT-201
Conditions: Inflammatory Bowel Disease (IBD); Ulcerative Colitis (UC); Crohn's Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria-Crohn's Disease:
- Diagnosis of Crohn's Disease (CD), as confirmed by endoscopy and histopathology
- Moderately to severely active CD as defined by Clinical Disease Activity Index (CDAI) and Simple Endoscopic Score (SES-CD)
- Meets drug stabilization requirements
Inclusion Criteria-Ulcerative Colitis
- Diagnosis of Ulcerative Colitis (UC), as confirmed by endoscopy and histopathology
- Moderately to severely active UC as defined by a 3-component MMCS
- Meets drug stabilization requirements
Exclusion Criteria-Crohn's Disease:
- Diagnosis of indeterminate colitis
- Suspected or diagnosed intra-abdominal or perianal abscess at Screening
- Previous small bowel resection with combined resected length of > 100 cm or previous colonic resection of > 2 segments
- CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or ileal involvement
Exclusion Criteria-Ulcerative Colitis
- Current evidence or within recent history (within last 6 months) of fulminant colitis, toxic megacolon, or bowel perforation
- Current stoma or impending need for colostomy or ileostomy
- Received IV corticosteroids within 14 days prior to Screening or during the Screening Phase
- Previous total proctocolectomy or subtotal colectomy
Recruiting US locations
Mirador Therapeutics Selected Site
Birmingham, AL 35235
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Scottsdale, AZ 85258
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Sun City, AZ 85351
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Little Rock, AR 72205
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Little Rock, AR 72211
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Colorado Springs, CO 80921
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Littleton, CO 80120
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Miami, FL 33134
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Miami, FL 33165
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Miami, FL 33176
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Orlando, FL 32825
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Palmetto Bay, FL 33176
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Pensacola, FL 32504
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Atlanta, GA 30342
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Snellville, GA 30078
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Glenview, IL 60026
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Gurnee, IL 60031
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Lafayette, LA 70503
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Marrero, LA 70072
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Shreveport, LA 71105
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Ypsilanti, MI 48197
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Bridgeton, MO 63044
Site contact: ASCEND-IBD Trial Center · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Kansas City, MO 64114
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Liberty, MO 64068
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Las Vegas, NV 89128
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
New York, NY 10016
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Rochester, NY 14618
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
High Point, NC 27262
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Raleigh, NC 27612
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Cincinnati, OH 45219
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Liberty Township, OH 45044
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Providence, RI 02904
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Greenville, SC 29607
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Cordova, TN 38018
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Dallas, TX 75230
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Garland, TX 75044
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Georgetown, TX 78628
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Houston, TX 77090
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Lubbock, TX 79424
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Southlake, TX 76092
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Tyler, TX 75701
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Webster, TX 77598
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Bellevue, WA 98004
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Silverdale, WA 98383
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Tacoma, WA 98405
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Mirador Therapeutics Selected Site
Milwaukee, WI 53215
Site contact: ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com
Study contacts (from the official record)
- ASCEND-IBD Trial Center · 844-206-4980 · clinicaltrials@miradortx.com